An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting

References

• Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012;109(5):742–753.
   PubMed Web of Science ®Google Scholar
• Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999;9(3):693–700.
   Google Scholar
• Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113.
   PubMed Web of Science ®Google Scholar
• Koivuranta M, Laara E, Snare L, et al. A survey of postoperative nausea and vomiting. Anaesthesia. 1997;52:443–449.
   PubMed Web of Science ®Google Scholar
• Eberhart LH, Mauch M, Morin AM, et al. Impact of a multimodal anti-emetic prophylaxis on patient satisfaction in high-risk patients for postoperative nausea and vomiting. Anaesthesia. 2002;57(10):1022–1027.
   PubMed Web of Science ®Google Scholar
• Scuderi PE. Pharmacology of antiemetics. Int Anesthesiol Clin. 2003;41(4):41–66.
   PubMedGoogle Scholar
• Hirsch J. Impact of postoperative nausea and vomiting in the surgical setting. Anaesthesia. 1994;49:30–33.
   PubMed Web of Science ®Google Scholar
• Apfel CC, Korttila K, Abdalla M, et al. IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441–2451.
   PubMed Web of Science ®Google Scholar
• Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS Recommendations For The Standardization And Interpretation Of The Electrocardiogram. JAC. 2009;53(11):982–991.
   Google Scholar
• McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol. Drugs. 2006;66(16):2123–2147.
   PubMed Web of Science ®Google Scholar
• White PF. Droperidol: a cost-effective antiemetic for over thirty years. Anesth Analg. 2002;95:789–790.
   PubMed Web of Science ®Google Scholar
• Habib AS, Gan TJ. Pro: the food and drug administration black box warning on droperidol is not justified. Anesth Analg. 2008;106:1414–1417.
   PubMed Web of Science ®Google Scholar
• Halloran K, Barash PG. Inside the black box: current policies and concerns with the United States Food and Drug Administration’s highest drug safety warning system. Curr Opin Anaesthesiol. 2010;23:423–427.
   PubMed Web of Science ®Google Scholar
• Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother. 1995;29(2):152–160.
   PubMed Web of Science ®Google Scholar
• Mogwitz S, Buse J, Wolff N, et al. Update on the pharmacological treatment of tics with dopamine-modulation agents. ACS Chem Neurosci. 2018;9(4):651–672.
   PubMed Web of Science ®Google Scholar
• Cesarani A, Alpini D, Monti B, et al. The treatment of acute vertigo. Neurol Sci. 2004;25(1):26–30.
   Google Scholar
• Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian ®): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14:209–218.
   PubMed Web of Science ®Google Scholar
• Solian Product Information. 2006. [cited 2020 Jan 16]. Available from: http://www.mentalmeds.org/prescription_meds/Solian.pdf
   Google Scholar
• Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7(3):247–253.
   PubMed Web of Science ®Google Scholar
• Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83–97.
   PubMed Web of Science ®Google Scholar
• Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7a antagonist: relevanve for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119–128.
   PubMed Web of Science ®Google Scholar
• Perrault GH, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):73–82.
   PubMed Web of Science ®Google Scholar
• Grattan V, Vaino AR, Prensky Z, et al. Antipsychotic benzamides amisulpride and LB-102 display polypharmacy as racemates, S enantiomers engage receptors D2 and D3, while R enantiomers engage 5-HT7. ACS Omega. 2019;4(9):14151–14154.
   PubMed Web of Science ®Google Scholar
• Fox GM, Roffel AF, Harsstra J, et al. Metabolism and excretion of intravenous, radio-labeled amisulpride in healthy, adult volunteers. Clin Pharmacol. 2019;11:161–169.
   PubMed Web of Science ®Google Scholar
• Rosenzweig P, Canal M, Patat A, et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1–13.
   PubMed Web of Science ®Google Scholar
• Hamon-Vilcot B, Chaufour S, Deschamps C, et al. Safety and pharmacokinetics following a single oral dose of amisulpride administered in healthy elderly volunteers. Eur J Clin Pharmacol. 1998;54(5):405–409.
   PubMed Web of Science ®Google Scholar
• Coukell AJ, Spencer CM, Benfield P. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs. 1996;6(3):237–256.
   Web of Science ®Google Scholar
• Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2001;18(3):173–199.
   Google Scholar
• Gillet G, Dormerque L, Canal M, et al. Amisulpride does not inhibit cytochrome P450 Isozymes. Eur Neuropsychopharmacol. 2000;10:331–332.
   Google Scholar
• Kranke P, Eberhart L, Motsch J, et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth. 2013;111(6):938–945.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Kranke P, Minkowitz HS, et al. Intravenous amisulpride for the prevention of postoperative nausea and vomiting: two concurrent, randomized, double-blind, placebo-controlled trials. Anesthesiology. 2017;126:268–275.
   PubMed Web of Science ®Google Scholar
• Kranke P, Bergese SD, Minkowitz HS, et al. Amisulpride prevents postoperative nausea and vomiting in patients at high risk: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2018;128(6):1099–1106.
   PubMed Web of Science ®Google Scholar
• Candiotti KA, Kranke P, Bergese SD, et al. Randomized, double-blind, placebo-controlled study of intravenous amisulpride as treatment of established postoperative nausea and vomiting in patients who have had no prior prophylaxis. Anesth Analg. 2019;128(6):1098–1105.
   PubMed Web of Science ®Google Scholar
• Habib A, Kranke P, Bergese S, et al. Amisulpride for the rescue treatment of postoperative nausea or vomiting in patients failing prophylaxis: a randomized, placebo-controlled phase III trial. Anesthesiology. 2019;130(2):203–212.
   PubMed Web of Science ®Google Scholar
• Smyla N, Eberhart L, Weibel S, et al. Amisulpride for the prevention and treatment of postoperative nausea and vomiting: A quantitative systematic review (meta-analysis). Drugs Future. 2019;44(6):453.
   Web of Science ®Google Scholar
• Herrstedt J, Summers Y, Daugaard G, et al. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. Support Care Cancer. 2018;26(1):139–145.
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Summers Y, Jordan K, et al. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose ranging trial. Support Care Cancer. 2019;27(7):2699–2705.
   PubMed Web of Science ®Google Scholar
• Täubel J, Ferber G, Fox G, et al. Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. Br J Clin Pharmacol. 2017;83(2):339–348.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Mouch CM. Amisulpride: a new dopamine antagonist for treatment of postoperative nausea and vomiting. Anesth Analg. 2019;128(6):1074–1076.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Gilbert JC, Gristwood RW, Cooper N, et al. The use of amisulpride as an anti-emetic. Internation patent application number PCT/GB201 1/050472. International Publication Number: WO2011110854A3 (2011)
   Google Scholar
• Habib AS, Gan TJ. The use of droperidol before and after the food and drug administration black box warning: a survey of the members of the society of ambulatory anesthesia. J Clin Anesth. 2008;20(1):35–39.
   PubMed Web of Science ®Google Scholar
• Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ. 2006;333(7563):324.
   PubMedGoogle Scholar
• Schnabel A1, Eberhart LH, Muellenbach R, et al. Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review. Eur J Anaesthesiol. 2010;27:1044–1051.
   PubMed Web of Science ®Google Scholar
• Okafor D, Kaye AD, Kaye RJ, et al. The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting. J Anaesthesiol Clin Pharmacol. 2017;33(4):441–445.
   PubMedGoogle Scholar